Background. Epicardial adipose tissue (EAT) has been described in the general population as an independent risk marker for incident coronary artery disease. In hemodialysis patients, it correlates with other markers of cardiovascular disease, but it is unknown if it is associated with adverse events. Methods. post hoc analysis of the Renagel in New Dialysis (RIND) patients study, a randomized trial of sevelamer versus calcium-based phosphate binders in 109 incident hemodialysis patients, followed for all-cause mortality for a median of 49.3 months. Patients underwent baseline cardiac computed tomography imaging within 120 days of dialysis initiation. Results. Baseline EAT measurements were available in 95 patients; EAT was positively correlated with age, body mass index, triglycerides, C-reactive protein, coronary artery calcium and aortic calcium, and negatively correlated with systolic and diastolic blood pressure, serum high density lipoprotein (HPL) cholesterol and serum phosphate (all P < 0.05). During followup, a total of 27 (28.4%) patients expired [mortality per 1000 patients/year: 95% confidence interval (95% CI) = 77 (64-94)]. Five-year survival rate was 44. 6% (95% CI: 21.1-65.7) and 71. in patients with EAT above or below the median, respectively. Each 10 cc increase in EAT volume was associated with a significant 6% increase in the risk of death during follow-up [hazard ratio (HR): 1.060; 95% CI: 1.013-1.109; P-value = 0.012].
A B S T R AC T
Background. Epicardial adipose tissue (EAT) has been described in the general population as an independent risk marker for incident coronary artery disease. In hemodialysis patients, it correlates with other markers of cardiovascular disease, but it is unknown if it is associated with adverse events. Methods. post hoc analysis of the Renagel in New Dialysis (RIND) patients study, a randomized trial of sevelamer versus calcium-based phosphate binders in 109 incident hemodialysis patients, followed for all-cause mortality for a median of 49.3 months. Patients underwent baseline cardiac computed tomography imaging within 120 days of dialysis initiation. Results. Baseline EAT measurements were available in 95 patients; EAT was positively correlated with age, body mass index, triglycerides, C-reactive protein, coronary artery calcium and aortic calcium, and negatively correlated with systolic and diastolic blood pressure, serum high density lipoprotein (HPL) cholesterol and serum phosphate (all P < 0.05). During followup, a total of 27 (28.4%) patients expired [mortality per 1000 patients/year: 95% confidence interval (95% CI) = 77 (64-94)]. Five-year survival rate was 44. 6% (95% CI: 21.1-65.7) and 71.2% (95% CI: 45.95-86.25) in patients with EAT above or below the median, respectively. Each 10 cc increase in EAT volume was associated with a significant 6% increase in the risk of death during follow-up [hazard ratio (HR): 1.060; 95% CI: 1.013-1.109; P-value = 0.012].
Conclusions. In this subanalysis of a randomized trial, EAT was an independent predictor of mortality in incident hemodialysis patients after ∼4 years of follow-up. These hypothesisgenerating findings will need confirmatory evidence.
I N T RO D U C T I O N
Epicardial adipose tissue (EAT) is adipose tissue sharing the same embriological origins as intrabdominal visceral adipose tissue (VAT) [1] . It is located below the parietal pericardium and in direct contact with the surface of the myocardium and the coronary artery adventitia (Figure 1 ). Like VAT, EAT produces a large amount of cytokines and proinflammatory mediators such as tumor necrosis factor-alpha and interleukin-6, and it is believed to promote atherosclerosis via paracrine effects [2, 3] . The direct contact with the coronary arteries of an inflammed EAT may induce vasa vasorum proliferation that penetrate through the arterial wall toward the intima and promote atherosclerosis [4] . The proatherosclerotic activity of the EAT is indirectly suggested by its close association with vulnerable atherosclerotic plaques and the risk of incident cardiovascular event [5] [6] [7] [8] .
Preliminary data in advanced stages of chronic kidney disease (CKD) patients linked EAT to the malnutritioninflammation-arteriosclerosis (MIA) [9] syndrome and markers of cardiovascular disease such as increased arterial stiffness [10] . However, these associations were substantially weakened after adjustment for confounders and whether EAT is associated with adverse events in dialysis (CKD-5D) patients has not been established. In this subanalysis of a previously published randomized trial [11] , we investigated the relationship between EAT and coronary artery calcium (CAC) as well as mortality in a cohort of incident hemodialysis patients. Given the post hoc nature of this study and its small size, the results of these analyses should be considered as hypothesisgenerating.
M AT E R I A L S A N D M E T H O D S

Study population
The study protocol has been previously described in detail and is summarized briefly here. The Renagel in New Dialysis (RIND) patients trial [11] was approved by the Ethics Committee at Tulane University New Orleans, LA; the study followed the principles of the Declaration of Helsinki, and an informed consent was obtained from all enrolled patients. We enrolled 109 adult hyperphoshatemic patients new to hemodialysis (randomized within 120 days of hemodialysis initiation) to study the effect of two phosphate-binding agents (i.e. sevelamer versus calcium-based binders) on the progression of CAC. The study population consisted of 109 women and men with CKD Stage 5 starting chronic hemodialysis, without a prior history of dialysis or kidney transplant, coronary artery bypass surgery or intracoronary stenting, atrial fibrillation or atrial flutter. These criteria were defined to ensure a homogeneous population (i.e. incident to dialysis patients), and to maximize image quality on electron beam computed tomography (EBCT) scanning by ensuring a minimum of artifacts due to metal or motion. Enrollment began in September 2000 and continued through December 2002. Written informed consent was obtained from all subjects before study-related procedures were performed, and the study was approved by a central Ethical Review Board.
Patients underwent an initial screening visit which included an assessment of their medical history, coronary heart disease risk profile and laboratory testing. If they met the inclusion/exclusion criteria, they were then eligible to undergo the baseline chest CT scan by means of EBCT and be randomized to treatment with either sevelamer or calcium carbonate or calcium acetate in a 1:1 ratio. The results of the primary end point of CAC progression have been published before [11] and will not be repeated here. Follow-up for all-cause mortality was continued till 31 December 2005 or until the date of death if it occurred before the end of 2005. Vital status verification was performed via the Social Security Death Index (SSDI) (http ://ssdi.rootsweb.com).
For the current analyses, we reviewed all available EBCT scans of adequate quality to measure EAT volume. Of the original 109 patients, 14 subjects were excluded from these analyses because of an error in the DICOM image storage, or because of an inadvertent exclusion of parts of the pericardium at the time of image acquisition. The clinical characteristics of the 14 excluded patients were similar to those of the 95 patients included in these analyses. 
Continued
Computed tomography imaging for coronary artery calcium and epicardial adipose tissue assessment EBCT scanning was performed with C-150 Imatron scanners (GE Imatron, San Francisco, CA). All scans were performed using a standardized protocol as previously described [11] . Thirty to 40, 3-mm thick slices were obtained from the carina to the diaphragm during a single breath hold. CAC was considered present if three or more contiguous pixels with an attenuation of 130 Hounsfield units (HU) or greater were detected along the course of the coronary artery tree. The CAC score was calculated according to the Agatston methodology [12] .
Using the Volume Analysis software on the Leonardo workstation (Siemens, Erlangen, Germany), EAT can be measured on the same axial images used for CAC scoring. The EAT is isolated by tracing the epicardium in the axial slices and setting a threshold of −190 to −30 HU (Figure 1 ). The fat voxels at the level of each cranio-caudal slice are then interpolated, and the sum of all voxels represent the total EAT volume in cc. All measurements were done by one experienced investigator, blinded to the patients' treatment and all other clinical data. The measurement of EAT on gated chest CT images is very reproducible [13] . In our laboratory, the inter-and intrareader variability of repeat EAT volume measurements are 1-5 cc.
Statistical analysis
The aims of current analyses were 2-fold: (i) to describe predictors of EAT volume at dialysis initiation and specifically CAC; (ii) to test the association between EAT volume and the risk of all-cause mortality in a cohort of patients incident to hemodialysis. Continuous variables are presented as mean (± standard deviation) or median (range), whereas categorical variables are presented as frequencies ( percentages). The study cohort was divided into low and high EAT volumes according to the median EAT value at baseline. Analysis of variance or Wilcoxon rank-sum test for numerical variables and χ 2 test or Fisher's exact test for categorical variables were used to compare baseline clinical characteristics between low and high EAT volume subjects. The Spearman correlation was employed to explore the relationship of baseline EAT with numerical variables such as age, body mass index (BMI) and laboratory variables, while Wilcoxon rank-sum test or Kruskal-Wallis test was used for categorical variables. A general linear model (GLM) was applied to identify the most parsimonious model to best predict EAT volume at baseline. All variables significantly associated with EAT volume (Pvalue <0.1) on univariate analysis were entered in the model, and the backward selection method with an alpha level of removal of 0.05 was used.
Survival rates for patients with EAT volume at baseline below or above the median were estimated by the Kaplan-Meier method and compared with the log-rank test [14] . A Cox proportional hazards (PH) model was further fitted to assess whether EAT at baseline and other covariates can predict allcause death and to identify the best predictive model of all-cause death [15] . All variables significantly associated with all-cause mortality (P-value <0.1) on univariate analysis were entered in to the model, and the backward selection method with an alpha level of removal of 0.05 was used. The interaction effects between CAC and EAT for the prediction of all-cause death were also examined with a Cox PH model after adjustment for age.
The ability of EAT to predict all-cause mortality was assessed with the C-index [16] , calibration statistics by Gronnesby and Borgan [17] , integrated discrimination improvement (IDI) and continuous net reclassification improvement (NRI) [18] [19] [20] . To evaluate the incremental value of EAT, models containing either age and CAC alone or age, CAC and EAT were compared. Statistical significance was set at P < 0.05 for all tests. The SAS statistical package version 9.3 (SAS Institute, Inc., Cary, NC) and R package version 2.15.0 (The R Foundation for Statistical Computing) were used for data management and analysis. 
R E S U LT S
The clinical characteristics of the 95 patients represented in this study are summarized in Table 1 .
The mean and median EAT volumes at baseline were larger (mean ± standard deviation: 129 ± 69.5 cc; median (range): 113 cc (30.88-467)) than in the general population and comparable to that of patients with coronary artery disease [21] . At baseline, EAT volume was larger in whites compared with other races. Furthermore, it was positively correlated with age, BMI, C-reactive protein (CRP), triglycerides, total CAC score and total aortic calcium score, and negatively correlated with systolic blood pressure, diastolic blood pressure, phosphorous, calcium × phosphorus product, corrected calcium × phosphorus product and serum HDL cholesterol (Tables 1 and 2 ). Figure 2 shows the correlation of EAT with CAC at baseline. Of note, there was no association between EAT and diabetes mellitus, hypertension, history of atherosclerotic cardiovascular disease or other clinical and laboratory characteristics. After adjusting for variables significantly associated with EAT in univariate analyses, age, gender, race, BMI, total CAC score and HDL cholesterol were significant predictors of EAT volume ( Table 3) .
The median follow-up time was 49.3 [95% confidence interval (95% CI) : 47.8-53.4) months], and 27 patients expired during the follow-up. Five-year survival rate was 44. 6% (95% CI: 21.1-65.7) and 71.2% (95% CI: 46.0-86.3) in patients with EAT volume above or below the median, respectively. Patients with EAT above the median had a greater chance of death compared with those with EAT below the median (Pvalue = 0.018; Figure 3 ).
On univariate survival analyses, each 10 cc EAT increase at baseline was associated with a significant 8.8% [hazard ratio (HR): 1.088; 95% CI: 1.042-1.136; P-value <0.001] increase in risk of all-cause mortality. In addition, CAC and age were significantly associated with all-cause mortality (Table 4 ); Figure 4 shows the hazard ratios of all-cause mortality for patients with CAC and EAT above and below the median alone or in combination.
On multivariable survival analyses, the strength of the association between EAT and mortality was not substantially changed (Table 5) . Each 10 cc increase in EAT volume was associated with a significant 6% increase in the risk of death during follow-up (HR: 1.060; 95% CI: 1.013-1.109; P-value = 0.012). Besides EAT, CAC and age were also significant predictors of all-cause mortality (Table 5 ). There was no interaction effect between CAC and EAT for the prediction of mortality after adjusting for age.
The addition of EAT to the model including age and CAC resulted in a small increase in the ability to classify all-cause mortality (likelihood ratio test, P-value = 0.02). C-statistic (95% CI) for the model with age and CAC was 0.738 (0.634-0.843), and it increased to 0.755 (0.657-0.854) when EAT was added. In addition, the model with EAT was well calibrated (P-value <0.001) and resulted in an improvement in NRI and IDI (Table 6 ). 
D I S C U S S I O N
In this re-analysis of the RIND study [11] , we provided the first description of a significant association of EAT with mortality in hemodialysis patients and confirmed the previously shown association of EAT with an important marker of vasculopathy and cardiovascular risk such as CAC. We further corroborated the predictive value of CAC for mortality, whereas we failed to confirm that binder selection was a predictor of outcome as shown in the parent trial [22] . However, 14 patients included in the original outcome analyses [22] were not included in the current study because of missing imaging information, and this may have caused a loss of predictive power. Given the post hoc nature of the study and the small sample size, these findings must be considered preliminary and in need of confirmatory evidence. EAT has emerged as a strong marker of cardiovascular risk in the general population, where it has been associated with events independently of other risk factors [7] . It would appear Ninety-five observations were used in the multivariable GLM. Significant variables on univariate analysis as summarized in Table 2 were included in the model. Backward selection with an alpha level of removal of 0.05 was used.
F I G U R E 3 : Kaplan-Meier curves displaying survival in patients with EAT volume below or above the median. The two-sided log-rank test was used to calculate the overall P-value for survival differences.
O R I G I N A L A R T I C L E
E p i c a r d i a l f a t a n d m o r t a l i t y that despite an association of EAT with measures of body size such as BMI, the noxious activities of an inflammed EAT are not strictly limited to overweight individuals. EAT is a source of inflammatory adipocytokines and has been shown to be densely infiltrated with lymphocytes, monocytes and macrophages in patients scheduled for elective bypass surgery [3] . In contrast, the same patients demonstrated minimal to no inflammatory changes in the subcutaneous adipose tissue [3] and a substantial inflammation of the adipose tissue in the peritoneal cavity [23] . The absence of a fascia separating the coronary arteries from the inflammed environment in which they are embedded may favor the development of atherosclerotic changes via direct paracrine effects [24] . As indirect confirmation of this hypothesis, anatomical and imaging studies have shown an association between unstable intracoronary plaque and inflammatory changes and enlargement of EAT [5, 6] . In numerous publications, EAT has been associated with severity of coronary artery disease, and in two populations-based studies it was an independent predictor of incident cardiovascular events [7, 8] . The interest in EAT in patients with CKD has emerged only recently and limited publications have shown its association with MIA [9] and vascular stiffness [10] , two conditions that affect a large number of patients undergoing dialysis. Ours is the first publication to show that EAT is a marker of mortality risk in CKD-5D patients. The findings may not come as a complete surprise since patients receiving chronic dialysis are well known to be highly inflammed and to be hosting a large burden of atherosclerosis [25] . Whether inflammed adipose tissue, either epicardial or peritoneal, may be the missing link between CKD Hazard ratio was calculated from a Cox proportional hazards model. Only variables with P-value <0.1 were shown.
F I G U R E 4 :
Hazard ratios for all-cause mortality for patients with CAC and EAT above and below the median alone or in combination.
and the disproportionately high cardiovascular morbidity and mortality demonstrated by these patients is an interesting hypothesis that deserves further investigation. EAT can be measured by magnetic resonance and echocardiography, although CT is considered more reproducible, particularly in comparison with echocardiography [26] . Nonetheless, to enhance the awareness of this new risk marker, it may be advisable to start adding remarks regarding EAT in standard echocardiographic reports, given the ease of performance and frequency with which these noninvasive tests are obtained in CKD patients. Whether regression of EAT volume can be induced with lifestyle changes and/or medical intervention has only recently been investigated. Nakazato et al. [27] showed a 2% regression of EAT at the end of 4 years of follow-up in 54 patients who lost 5% of their baseline body weight, as opposed to a 23% increase in EAT volume in the 71 subjects who gained >5% of their initial body weight. Alexopoulos et al. [28] reported that EAT volume regressed ∼3% after 1 year of intensive lipid-lowering therapy with atorvastatin in 194 postmenopausal hyperlipidemic women. Potential mechanisms include an antiinflammatory activity of statins and diet, as well as the inhibition of proliferating vasa vasorum, that are believed to contribute directly to the development of atherosclerosis [29] [30] [31] . The encouraging results of the recent SHARP trial (Study of Heart And Renal Protection) [32] , showing reduction in cardiovascular events in CKD patients treated with simvastatin/ezetimibe, may indeed relate to some antiinflammatory activity on visceral fat of these drugs [32] .
The current study was a subanalysis of the RIND trial designed to address the effect of sevelamer versus calcium-based phosphate binders on CAC progression in incident hemodialysis patients [11] . RIND was not designed to measure EAT, and power calculations were based on the expected change in the CAC score during a follow-up period of 18 months. As such, the results of these analyses cannot be directly exported to other CKD populations without further studies. Our study design did not allow us to define the cause of death of the a C-index with 4-year follow-up as a cutoff time point to define cases and controls [16] . b Gronnesby and Borgan test [17] . c Corresponds to the quantity defined as "1/2 NRI(>0)" in Pencina et al. [18] . CAC, total coronary artery calcium; EAT, epicardial adipose tissue; CI, confidence interval; LR, likelihood ratio; IDI, integrated discrimination improvement; NRI, net reclassification improvement. Table 4 were included in the model. Backward selection with an alpha level of removal of 0.05 was used.
patients we followed (the SSDI does not report the cause of death but simply the vital status of patients) and the number of subjects was relatively small. Hence, further studies are warranted to confirm and expand our findings.
In conclusion, in these analyses, we demonstrated that EAT is an independent predictor of mortality in incident CKD-5D patients. While the extent of EAT has been associated with the presence of subclinical atherosclerosis and adverse outcomes in the general population [7, 8] , this is the first report on the prognostic impact of EAT in CKD-5D patients. Future studies should address this emerging marker of risk in different CKD populations. Due to the ease with which it is measured, EAT may become a useful method to noninvasively assess the risk in CKD patients that are known to suffer from extremely high rates of cardiovascular diseases. The effect of various interventions on EAT will also deserve further investigation. 
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